Scholarlink

<p>Bilateral subthalamic nucleus Deep Brain Stimulation (STN-DBS) and Levodopa-Carbidopa Intestinal Gel (LCIG) represent established treatment options for complicated Parkinson’s disease (PD). Evidence regarding their effectiveness on axial symptoms remains limited, despite disability. This observational real-world cohort study included 317 PD patients who received STN-DBS (<i>N</i> = 203) or LCIG (<i>N</i> = 114) between 2005 and 2023 at two Italian centeres to compare their short- and long-term effects on axial symptoms. At baseline, LCIG group exhibited more severe axial and motor symptoms and higher prevalence of cognitive abnormalities than STN-DBS cohort. Longitudinally, LCIG treatment was associated with lower odds of long-term axial deterioration compared with STN-DBS, after adjustment for baseline differences and levodopa equivalent daily dose, despite an increased risk of dyskinesias. A significant treatment-by-time interaction suggested more favourable long-term axial symptom trajectories in the LCIG group.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

STN-DBS and LCIG differentially affect long-term axial symptoms in Parkinson’s disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月14日

查看全文
  • Fabiana Colucci,
  • Ahmet Kaymak,
  • Pietro Antenucci,
  • Andrea Gozzi,
  • Antonio Emanuele Elia,
  • Roberto Cilia,
  • Valentina Leta,
  • Arianna Braccia,
  • Nico Golfrè Andreasi,
  • Gianfranco Gaudiano,
  • Grazia Devigili,
  • Francesco Pirone,
  • Mattia Tosi,
  • Alberto Mazzoni,
  • Luigi Michele Romito,
  • Roberto Eleopra,
  • Maura Pugliatti,
  • Mariachiara Sensi

摘要

Bilateral subthalamic nucleus Deep Brain Stimulation (STN-DBS) and Levodopa-Carbidopa Intestinal Gel (LCIG) represent established treatment options for complicated Parkinson’s disease (PD). Evidence regarding their effectiveness on axial symptoms remains limited, despite disability. This observational real-world cohort study included 317 PD patients who received STN-DBS (N = 203) or LCIG (N = 114) between 2005 and 2023 at two Italian centeres to compare their short- and long-term effects on axial symptoms. At baseline, LCIG group exhibited more severe axial and motor symptoms and higher prevalence of cognitive abnormalities than STN-DBS cohort. Longitudinally, LCIG treatment was associated with lower odds of long-term axial deterioration compared with STN-DBS, after adjustment for baseline differences and levodopa equivalent daily dose, despite an increased risk of dyskinesias. A significant treatment-by-time interaction suggested more favourable long-term axial symptom trajectories in the LCIG group.